Theravance shares fall as late-stage trial for Yupelri fails by Technical Terrence Team 01/05/2024 0 mi-viri/iStock via Getty Images Theravance Biopharmacy (NASDAQ: TBPH) lost ~16% premarket on Friday after announcing that Yupelri, its FDA-approved therapy ...